Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
AMPH Amphastar Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: AMPH
Price (delayed)
$24.11
Market cap
$1.14B
P/E Ratio
8.26
Dividend/share
N/A
EPS
$2.92
Enterprise value
$1.61B
Amphastar is a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin active
Highlights
The stock's P/E is 90% less than its 5-year quarterly average of 83.9 and 31% less than its last 4 quarters average of 12.0
Amphastar Pharmaceuticals's equity has increased by 12% YoY and by 2.6% from the previous quarter
Amphastar Pharmaceuticals's quick ratio has increased by 14% YoY but it has decreased by 7% QoQ
The EPS has contracted by 11% from the previous quarter and by 9% YoY
The net income has contracted by 11% from the previous quarter and by 8% YoY
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.amphastar.com
Key stats
What are the main financial stats of AMPH
Market
Valuations
Earnings
Shares outstanding
47.14M
Market cap
$1.14B
Enterprise value
$1.61B
Price to earnings (P/E)
8.26
Price to book (P/B)
1.53
Price to sales (P/S)
1.57
EV/EBIT
8
EV/EBITDA
6.05
EV/Sales
2.2
Revenue
$730.66M
Gross profit
$369.01M
Operating income
$194.7M
Net income
$141.63M
EBIT
$200.77M
EBITDA
$265.38M
Free cash flow
$150.23M
Per share
Balance sheet
Liquidity
EPS
$2.92
EPS diluted
$2.76
Free cash flow per share
$3.15
Book value per share
$15.77
Revenue per share
$15.34
TBVPS
$21.87
Total assets
$1.63B
Total liabilities
$874.99M
Debt
$652.53M
Equity
$751.28M
Working capital
$388.91M
Debt to equity
0.87
Current ratio
2.95
Quick ratio
1.93
Net debt/EBITDA
1.77
Margins
Efficiency
Dividend
EBITDA margin
36.3%
Gross margin
50.5%
Net margin
19.4%
Operating margin
26.6%
Return on assets
9.1%
Return on equity
19.4%
Return on invested capital
15.9%
Return on capital employed
14.1%
Return on sales
27.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AMPH stock price
How has the Amphastar Pharmaceuticals stock price performed over time
Intraday
-2.19%
1 week
-1.59%
1 month
-4.44%
1 year
-43.18%
YTD
-35.07%
QTD
-16.83%
Financial performance
How have Amphastar Pharmaceuticals's revenue and profit performed over time
Revenue
$730.66M
Gross profit
$369.01M
Operating income
$194.7M
Net income
$141.63M
Gross margin
50.5%
Net margin
19.4%
AMPH's net margin is down by 15% year-on-year and by 11% since the previous quarter
AMPH's operating margin is down by 15% year-on-year and by 5% since the previous quarter
The net income has contracted by 11% from the previous quarter and by 8% YoY
The operating income has declined by 8% year-on-year and by 5% since the previous quarter
Price vs fundamentals
How does AMPH's price correlate with its fundamentals
Growth
What is Amphastar Pharmaceuticals's growth rate over time
Valuation
What is Amphastar Pharmaceuticals stock price valuation
P/E
8.26
P/B
1.53
P/S
1.57
EV/EBIT
8
EV/EBITDA
6.05
EV/Sales
2.2
The stock's P/E is 90% less than its 5-year quarterly average of 83.9 and 31% less than its last 4 quarters average of 12.0
The EPS has contracted by 11% from the previous quarter and by 9% YoY
The price to book (P/B) is 47% lower than the 5-year quarterly average of 2.9 and 41% lower than the last 4 quarters average of 2.6
Amphastar Pharmaceuticals's equity has increased by 12% YoY and by 2.6% from the previous quarter
AMPH's price to sales (P/S) is 49% less than its 5-year quarterly average of 3.1 and 40% less than its last 4 quarters average of 2.6
Amphastar Pharmaceuticals's revenue has increased by 8% YoY
Efficiency
How efficient is Amphastar Pharmaceuticals business performance
The ROIC is down by 23% year-on-year and by 12% since the previous quarter
The ROE has contracted by 22% YoY and by 13% from the previous quarter
The ROS has contracted by 15% YoY and by 8% from the previous quarter
The company's return on assets fell by 12% QoQ and by 12% YoY
Dividends
What is AMPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AMPH.
Financial health
How did Amphastar Pharmaceuticals financials performed over time
The total assets is 86% greater than the total liabilities
Amphastar Pharmaceuticals's current ratio has increased by 35% YoY but it has decreased by 3.9% from the previous quarter
Amphastar Pharmaceuticals's quick ratio has increased by 14% YoY but it has decreased by 7% QoQ
AMPH's debt is 13% smaller than its equity
Amphastar Pharmaceuticals's equity has increased by 12% YoY and by 2.6% from the previous quarter
Amphastar Pharmaceuticals's debt to equity has decreased by 6% YoY and by 2.2% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.